604 related articles for article (PubMed ID: 25344617)
1. Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus.
Doğan V; Yeşil Ş; Kayalı Ş; Beken S; Özgür S; Ertuğrul İ; Bozkurt C; Örün UA; Karademir S
J Trop Pediatr; 2015 Feb; 61(1):74-7. PubMed ID: 25344617
[TBL] [Abstract][Full Text] [Related]
2. Regression of a cardiac rhabdomyoma in a patient receiving everolimus.
Tiberio D; Franz DN; Phillips JR
Pediatrics; 2011 May; 127(5):e1335-7. PubMed ID: 21464184
[TBL] [Abstract][Full Text] [Related]
3. Everolimus for severe arrhythmias in tuberous sclerosis complex related cardiac rhabdomyomas.
Silva-Sánchez MP; Alvarado-Socarras JL; Castro-Monsalve J; Meneses KM; Santiago J; Prada CE
Am J Med Genet A; 2021 May; 185(5):1525-1531. PubMed ID: 33590972
[TBL] [Abstract][Full Text] [Related]
4. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex.
Goyer I; Dahdah N; Major P
Pediatr Neurol; 2015 Apr; 52(4):450-3. PubMed ID: 25682485
[TBL] [Abstract][Full Text] [Related]
5. Everolimus treatment of a newborn with rhabdomyoma causing severe arrhythmia.
Öztunç F; Atik SU; Güneş AO
Cardiol Young; 2015 Oct; 25(7):1411-4. PubMed ID: 26339757
[TBL] [Abstract][Full Text] [Related]
6. Prenatal diagnosis of giant cardiac rhabdomyoma in tuberous sclerosis complex: a new therapeutic option with everolimus.
Mlczoch E; Hanslik A; Luckner D; Kitzmüller E; Prayer D; Michel-Behnke I
Ultrasound Obstet Gynecol; 2015 May; 45(5):618-21. PubMed ID: 24913039
[TBL] [Abstract][Full Text] [Related]
7. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
8. Everolimus for the Treatment of Tuberous Sclerosis Complex-Related Cardiac Rhabdomyomas in Pediatric Patients.
Dahdah N
J Pediatr; 2017 Nov; 190():21-26.e7. PubMed ID: 28888564
[No Abstract] [Full Text] [Related]
9. Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma.
Demir HA; Ekici F; Yazal Erdem A; Emir S; Tunç B
Pediatrics; 2012 Jul; 130(1):e243-7. PubMed ID: 22732179
[TBL] [Abstract][Full Text] [Related]
10. Rapid resolution of cardiac rhabdomyomas following everolimus therapy.
Choudhry S; Nguyen HH; Anwar S
BMJ Case Rep; 2015 Dec; 2015():. PubMed ID: 26661560
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Rhabdomyomas in Tuberous Sclerosis Complex.
Castro-Monsalve J; Alvarado-Socarras JL; Mantilla KA; Forero L; Moreno A; Prada CE
J Pediatr; 2018 Jan; 192():264-264.e1. PubMed ID: 29128117
[No Abstract] [Full Text] [Related]
12. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
13. Everolimus-induced near-resolution of giant cardiac rhabdomyomas and large renal angiomyolipoma in a newborn with tuberous sclerosis complex.
Colaneri M; Quarti A; Pozzi M
Cardiol Young; 2016 Jun; 26(5):1025-8. PubMed ID: 27055516
[TBL] [Abstract][Full Text] [Related]
14. Rapid response of a cardiac rhabdomyoma causing severe right ventricular outflow obstruction to Sirolimus in an infant with negative genetics for Tuberous sclerosis.
Nir-David Y; Brosilow S; Khoury A
Cardiol Young; 2021 Feb; 31(2):312-314. PubMed ID: 33148352
[TBL] [Abstract][Full Text] [Related]
15. Rapid regression of large cardiac rhabdomyomas in neonates after sirolimus therapy.
Weiland MD; Bonello K; Hill KD
Cardiol Young; 2018 Mar; 28(3):485-489. PubMed ID: 29233209
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
[TBL] [Abstract][Full Text] [Related]
17. [Rapamycin in the treatment of cardiac rhabdomyoma associated with tuberous sclerosis complex].
Pang LY; Zou LP; Huang LL; Gao Y; Ma SF; Zhang MN; Wang YY
Zhonghua Er Ke Za Zhi; 2016 Jun; 54(6):424-7. PubMed ID: 27256228
[TBL] [Abstract][Full Text] [Related]
18. Possible prevention of tuberous sclerosis complex lesions.
Kotulska K; Borkowska J; Jozwiak S
Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
[TBL] [Abstract][Full Text] [Related]
19. Everolimus for cardiac rhabdomyomas in children with tuberous sclerosis. The ORACLE study protocol (everOlimus for caRdiac rhAbdomyomas in tuberous sCLErosis): a randomised, multicentre, placebo-controlled, double-blind phase II trial.
Stelmaszewski EV; Parente DB; Farina A; Stein A; Gutierrez A; Raquelo-Menegassio AF; Manterola C; de Sousa CF; Victor C; Maki D; Morón EM; de Abrantes FF; Iqbal F; Camacho-Vilchez J; Jimenez-Pavón J; Polania JP; Thompson L; Bonanato L; Diebold M; Da Silva MVCP; Nashwan MWJ; Galvani MAG; Idris OEA; Danos P; Ortiz-Lopez R; Mahmoud RAA; Gresse S; Loss KL
Cardiol Young; 2020 Mar; 30(3):337-345. PubMed ID: 31983379
[TBL] [Abstract][Full Text] [Related]
20. Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment.
Yıldırım S; Aypar E; Aydın B; Akyüz C; Aykan HH; Ertuğrul İ; Karagöz T; Alehan D
Turk J Pediatr; 2023; 65(3):479-488. PubMed ID: 37395967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
